SAN FRANCISCO – July 21, 2022 – InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced that it has expanded its global presence with the opening of multiple new locations in Asia-Pacific and North America. The company’s new facilities include Mandaluyong, Philippines; Kuala Lumpur, Malaysia; Melbourne, Australia; and San Diego, California, adding a large footprint of state-of-the-art laboratories and office space for scaling up InterVenn’s software development, technical support, clinical research and business development.
“Our global expansion reflects the significant opportunity to apply glycoproteomics to improve clinical decision-making and translational research on a worldwide scale,” said Aldo Carrascoso, CEO of InterVenn Biosciences. “Our new offices and laboratory space will enable us to scale our operations, better connect with biomedical hubs, access local talent and serve different regions with localized resources.”
With facilities already established in San Francisco and Southeast Asia, InterVenn is building on its momentum since it was started with the mission that “no one should ever be blindsided by disease.” Each new location will play a key role in the increasing efforts to advance the company on its mission:
- San Diego – InterVenn’s new presence in southern California will give the company access to the thriving San Diego life science community. Corporate business development, sales, marketing and other non-laboratory personnel work out of this new facility.
- Australia – InterVenn’s new presence in Melbourne will enable the company to increase scientific collaborations, connect with talent in ML/AI and informatics, and have broader access to clinical samples and biobanking.
- Philippines – InterVenn’s expanded presence in the Philippines will allow the company to scale its software engineering and IT capabilities to support current and future development and commercial activities.
- Malaysia – InterVenn’s presence in Malaysia will allow the company to expand its R&D and clinical laboratory functions, enabling footprint expansion into Asia-Pacific. Also, a local Business Development and general administration team will drive regional partnerships, collaborations and commercial activities.